• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.

作者信息

Wrenger Eike, Müller Regina, Moesenthin Michael, Welte Tobias, Frölich Jürgen C, Neumann Klaus H

机构信息

Division of Nephrology, Department of Internal Medicine, Otto-von-Guericke-University, Leipziger Strasse 44, D-39120 Magdeburg, Germany.

出版信息

BMJ. 2003 Jul 19;327(7407):147-9. doi: 10.1136/bmj.327.7407.147.

DOI:10.1136/bmj.327.7407.147
PMID:12869459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1126510/
Abstract
摘要

相似文献

1
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.螺内酯与血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的相互作用：44例分析。
BMJ. 2003 Jul 19;327(7407):147-9. doi: 10.1136/bmj.327.7407.147.
2
Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.给予螺内酯加呋塞米并联合马来酸依那普利、氯沙坦钾或坎地沙坦酯的慢性心力衰竭患者的血清钾浓度。
J Clin Pharm Ther. 2005 Dec;30(6):603-10. doi: 10.1111/j.1365-2710.2005.00694.x.
3
Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.血管紧张素转换酶抑制剂与螺内酯联合治疗导致高钾血症性晕厥。
Kardiol Pol. 2010 Sep;68(9):1043-5; discussion 1046.
4
Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.在联合使用血管紧张素受体阻滞剂坎地沙坦和螺内酯治疗期间出现危及生命的高钾血症。
Kobe J Med Sci. 2005;51(1-2):1-6.
5
[Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases].[服用螺内酯治疗充血性心力衰竭患者的高钾血症和肾功能损害。对125例连续病例的回顾性分析]
Ugeskr Laeger. 2004 Sep 6;166(37):3201-3.
6
[Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].[危险高钾血症作为心力衰竭新治疗策略的后遗症]
Praxis (Bern 1994). 2000 Dec 7;89(49):2073-6.
7
[Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].螺内酯和血管紧张素转换酶抑制剂治疗导致的药物相关性高钾血症
Pol Merkur Lekarski. 1999 Aug;7(38):69-70.
8
Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.利用真实生活数据探讨高钾血症风险以及螺内酯与长效血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂联合治疗心力衰竭的情况：一项基于人群和保险的队列研究
Pharmacoepidemiol Drug Saf. 2015 Apr;24(4):406-13. doi: 10.1002/pds.3748. Epub 2015 Feb 12.
9
[An elderly man with known heart failure admitted with cardiogenic shock].一名患有已知心力衰竭的老年男性因心源性休克入院。
Tidsskr Nor Laegeforen. 2010 Jul 1;130(13):1352-4. doi: 10.4045/tidsskr.09.0384.
10
Drug safety in patients with heart failure.
Arch Intern Med. 2005 Jan 10;165(1):118. doi: 10.1001/archinte.165.1.118-a.

引用本文的文献

1
Epigenetics of Hypertensive Nephropathy.高血压肾病的表观遗传学
Biomedicines. 2024 Nov 16;12(11):2622. doi: 10.3390/biomedicines12112622.
2
Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk.射血分数保留的心力衰竭合并慢性肾脏病患者中螺内酯剂量与预后的关联——疗效与风险的平衡
Front Pharmacol. 2023 Jan 27;14:1084442. doi: 10.3389/fphar.2023.1084442. eCollection 2023.
3
An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.肾素-血管紧张素-醛固酮系统（RAAS）阻滞剂的临床必需和药效学显著药物相互作用概述。
Curr Cardiol Rev. 2022;18(6):e110522204611. doi: 10.2174/1573403X18666220511152330.
4
Polypharmacy in the Management of Arterial Hypertension-Friend or Foe?高血压的药物治疗管理：多药并用是友是敌？
Medicina (Kaunas). 2021 Nov 23;57(12):1288. doi: 10.3390/medicina57121288.
5
Additional Information Necessary.所需的额外信息。
Dtsch Arztebl Int. 2021 Jan 11;118(1-2):11-12. doi: 10.3238/arztebl.m2021.0045.
6
The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity.多种降压药物类别与性别、种族和民族的阿尔茨海默病发病率的关联。
PLoS One. 2018 Nov 1;13(11):e0206705. doi: 10.1371/journal.pone.0206705. eCollection 2018.
7
Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot).一项试点研究，旨在测试在基层医疗中对多重疾病的多重用药进行优先排序的试验设计和复杂干预措施（PRIMUMpilot）的可行性。
BMJ Open. 2016 Jul 25;6(7):e011613. doi: 10.1136/bmjopen-2016-011613.
8
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病患者血钾水平的影响：一项汇总分析
Diabetes Ther. 2016 Mar;7(1):125-37. doi: 10.1007/s13300-015-0150-y. Epub 2016 Jan 12.
9
Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).盐皮质激素受体拮抗剂在射血分数降低的心力衰竭合并糖尿病住院患者中的应用（来自EVEREST试验）
Am J Cardiol. 2014 Sep 1;114(5):743-50. doi: 10.1016/j.amjcard.2014.05.064. Epub 2014 Jun 24.
10
Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).螺内酯的使用与射血分数＜45%且估算肾小球滤过率＜45 ml/min/1.73 m(2.)的心力衰竭 Medicare 受益人心力衰竭再住院率升高相关。
Am J Cardiol. 2014 Jul 1;114(1):79-82. doi: 10.1016/j.amjcard.2014.03.062. Epub 2014 Apr 18.

本文引用的文献

1
Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.63至85岁患有亚临床肾病的充血性心力衰竭患者的高钾血症
Am J Cardiol. 2002 Sep 15;90(6):663-5. doi: 10.1016/s0002-9149(02)02581-x.
2
Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.估算肾小球滤过率以预防因螺内酯与血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂联合治疗导致的危及生命的高钾血症。
Am J Cardiol. 2002 Sep 15;90(6):662-3. doi: 10.1016/s0002-9149(02)02580-8.
3
Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.危及生命的高钾血症：一名肾功能不全患者因使用螺内酯治疗心力衰竭而引发的并发症。
Anesth Analg. 2002 Jul;95(1):39-41, table of contents. doi: 10.1097/00000539-200207000-00006.
4
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.血管紧张素转换酶抑制剂与螺内酯联合治疗期间危及生命的高钾血症：25例分析
Am J Med. 2001 Apr 15;110(6):438-41. doi: 10.1016/s0002-9343(01)00642-8.
5
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.服用螺内酯的慢性心力衰竭患者经历的严重不良事件。
Heart. 2001 Apr;85(4):E8. doi: 10.1136/heart.85.4.e8.
6
Elderly heart failure patients with drug-induced serious hyperkalemia.
Aging (Milano). 2000 Aug;12(4):315-9. doi: 10.1007/BF03339853.
7
Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES.低剂量螺内酯仅在与血管紧张素转换酶抑制剂联合使用时，才会使充血性心力衰竭患者的利钠作用显著增强：支持RALES试验的机制证据
Circulation. 2000 Nov 7;102(19):2325-8. doi: 10.1161/01.cir.102.19.2325.
8
Spironolactone and congestive heart-failure.螺内酯与充血性心力衰竭
Lancet. 2000 Apr 15;355(9212):1369-70. doi: 10.1016/S0140-6736(05)72606-4.
9
ABC of heart failure. Acute and chronic management strategies.心力衰竭基础。急性和慢性管理策略。
BMJ. 2000 Feb 26;320(7234):559-62. doi: 10.1136/bmj.320.7234.559.
10
Diuretic complications.利尿并发症。
Am J Med Sci. 2000 Jan;319(1):10-24.